Dem lashes out at Bessent during heated committee hearing exchange: 'Excuse me'
"Ma'am, that's incorrect," Bessent said in a response to a chart displayed by Plaskett, which was referencing the cost of living, but the chart only went until February of this year.
"Excuse me. Let me get something straight with you first here. I've seen you interrupt everyone. When you come to someone's house, you respect their rules. And in this house, we don't interrupt individuals. And you're not going to interrupt my time," Plaskett said.
"I'm going to give you time to respond. You may want to jot down some notes about things you don't agree with me on so you can respond to them at that time. But while I'm speaking, as the person holding this time, you will refrain from speaking, sir, until I'm done, until I'm done, then I will give you time to speak, OK?" she continued.
Democrat Congresswoman Draws Boos Over 'Shameful' Sexism Remark In Committee Hearing With Treasury Secretary
"I look forward to facts," Bessent replied.
Read On The Fox News App
"Thank you. I'll look forward to your response whether they're factual or incorrect either," Plaskett replied.
Later on, Rep. Nathaniel Moran, R-Texas, asked Bessent, "Where did [Plaskett] go wrong in her statement?"
"Well, first of all, I would fire the staffer who did that chart, because it stopped in February 2025 and prices are down substantially since then. But that's an inconvenient truth. Secondly, the S&P, if the congresswoman would care to check Bloomberg. The stock market is judged by the S&P, which is the most widely held index by American 401ks is up on the air, up," Bessent said.
Treasury Secretary Scott Bessent Denies That Tariff Pause Is Due To Market Declines
When Plaskett attempts to interject, Moran says, "Excuse me, ma'am, it's my time."
"And we don't interrupt, excuse me, we don't interrupt is what I learned," Bessent clapped back. "Since Jan. 1, it is my business for 40 years to know what the stock market does, and it is up in the air."
After the hearing, Plaskett received a range of criticism, including a remark from an X user saying, "Do all these twats have their PMS cycle synced? Someone needs to ship a case of Midol to the Capitol this afternoon."
Small Businesses Barely Survived Biden. They Can't Wait For Tariffs To Fix Things
Plaskett replied to the user's response with an explicit comment.
"Excuse you!! This twat, [c--t], pum pum whatever you want to call it represents an organ that gives LIFE and is resilienr [sic] so thanks for the compliment. I can take one interruption but Bessent was out of control. And…. I know I look good for my age but baby I'm post menopausal and it still works," she replied, with emojis of cherries and a drop of water.
The primary focus of the committee hearing was on trade and tax policies, both of which have sparked serious debate as Congress works through the reconciliation bill, and as the administration negotiates trade deals with other nations. As for Bessent, he'll be on Capitol Hill again on Thursday testifying before the Senate Finance Committee.Original article source: Dem lashes out at Bessent during heated committee hearing exchange: 'Excuse me'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today
Key Points Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P 500 index fund. Still, Pfizer today offers a fat dividend and plenty of growth potential. 10 stocks we like better than Pfizer › Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (NYSE: PFE) three years ago and hung on? Well, I'm afraid the answer isn't pretty: If you'd investing $1,000 in Pfizer on Aug. 8, 2022, hung on and reinvested dividends, that sum would have been worth $585 on Aug. 8, 2025. Ouch! For some context, during those same three years, the S&P 500 index of 500 of America's biggest companies averaged gains of roughly 17% per year, turning $1,000 into $1,615. Here's some good news, though: Stock investors need to look forward much more than backward. Trailing returns are in the past. What matters most for current Pfizer investors and would-be Pfizer investors is how the company will perform from here on. And Pfizer's future is looking promising. Some investors have been disappointed in Pfizer when they've compared recent results to those from the past. But those past years were exceptional boom years thanks to Pfizer's COVID-19 vaccine and Paxlovid COVID-19 treatment. Those were in great demand, but demand has fallen. Others worry because some of Pfizer's big sellers, such as Eliquis, Ibrance, Inlyta, Xeljanz, Xtandi, and Vyndaqel, are coming off patent protection in the next few years. Pfizer has been planning for that, and investing in its pipeline, which features more than 100 active programs -- many of which are in oncology. Pfizer has also been getting additional approvals for its drugs, and it has been cutting its costs in an effort to boost profitability. Finally, Pfizer is a dividend-paying stock, with a whopping recent dividend yield of 7%. So as you invest in Pfizer and wait for its investments to pay off, you'll be rewarded. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Selena Maranjian has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Republicans, Democrats alike exhort Trump: Keep security pact with Australia and UK alive
Congress AUKUS WASHINGTON (AP) — U.S. lawmakers from both parties are urging the Trump administration to maintain a three-way security partnership designed to supply Australia with nuclear-powered submarines — a plea that comes as the Pentagon reviews the agreement and considers the questions it has raised about the American industrial infrastructure's shipbuilding capabilities. Two weeks ago, the Defense Department announced it would review AUKUS, the 4-year-old pact signed by the Biden administration with Australia and the United Kingdom. The announcement means the Republican administration is looking closely at a partnership that many believe is critical to the U.S. strategy to push back China's influence in the Indo-Pacific. The review is expected to be completed in the fall. 'AUKUS is essential to strengthening deterrence in the Indo-Pacific and advancing the undersea capabilities that will be central to ensuring peace and stability," Republican Rep. John Moolenaar of Michigan and Democratic Rep. Raja Krishnamoorthi of Illinois wrote in a July 22 letter to Defense Secretary Pete Hegseth. Moolenaar chairs the House panel on China and Krishnamoorthi is its top Democrat. The review comes as the Trump administration works to rebalance its global security concerns while struggling with a hollowed-out industrial base that has hamstrung U.S. capabilities to build enough warships. The review is being led by Elbridge Colby, the No. 3 Pentagon official, who has expressed skepticism about the partnership. 'If we can produce the attack submarines in sufficient number and sufficient speed, then great. But if we can't, that becomes a very difficult problem," Colby said during his confirmation hearing in March. 'This is getting back to restoring our defense industrial capacity so that we don't have to face these awful choices but rather can be in a position where we can produce not only for ourselves, but for our allies." US cannot build enough ships As part of the $269 billion AUKUS partnership, the United States will sell three to five Virginia-class nuclear-powered submarines to Australia, with the first delivery scheduled as soon as 2032. The U.S. and the U.K. would help Australia design and build another three to five attack submarines to form an eight-boat force for Australia. A March report by the Congressional Research Service warned that the lack of U.S. shipbuilding capacities, including workforce shortage and insufficient supply chains, is jeopardizing the much-celebrated partnership. If the U.S. should sell the vessels to Australia, the U.S. Navy would have a shortage of attack submarines for two decades, the report said. The Navy has been ordering two boats per year in the last decade, but U.S. shipyards have been only producing 1.2 Virginia-class subs a year since 2022, the report said. 'The delivery pace is not where it needs to be" to make good on the first pillar of AUKUS, Admiral Daryl Caudle, nominee for the Chief of Naval Operations, told the Senate Armed Services Committee last month. Australia has invested $1 billion in the U.S. submarine industrial base, with another $1 billion to be paid before the end of this year. It has agreed to contribute a total of $3 billion to uplift the U.S. submarine base, and it has sent both industry personnel to train at U.S. shipyards and naval personnel for submarine training in the United States. "Australia was clear that we would make a proportionate contribution to the United States industrial base,' an Australian defense spokesperson said in July. 'Australia's contribution is about accelerating U.S. production rates and maintenance to enable the delivery of Australia's future Virginia-class submarines.' The three nations have also jointly tested communication capabilities with underwater autonomous systems, Australia's defense ministry said on July 23. Per the partnership, the countries will co-develop other advanced technologies, from undersea to hypersonic capabilities. At the recent Aspen Security Forum, Kevin Rudd, the Australian ambassador to the United States, said his country is committed to increasing defense spending to support its first nuclear-powered sub program, which would also provide 'massively expensive full maintenance repair facilities" for the U.S. Indo-Pacific fleet based in Western Australia. Rudd expressed confidence that the two governments 'will work our way through this stuff.' AUKUS called 'crucial to American deterrence' Bruce Jones, senior fellow with the Strobe Talbott Center for Security, Strategy and Technology, told The Associated Press that the partnership, by positioning subs in Western Australia, is helping arm the undersea space that is 'really crucial to American deterrence and defense options in the Western Pacific.' 'The right answer is not to be content with the current pace of submarine building. It's to increase the pace," Jones said. Jennifer Parker, who has served more than 20 years with the Royal Australian Navy and founded Barrier Strategic Advisory, said it should not be a zero-sum game. 'You might sell one submarine to Australia, so you have one less submarine on paper. But in terms of the access, you have the theater of choice from operating from Australia, from being able to maintain your submarines from Australia," Parker said. 'This is not a deal that just benefits Australia." Defense policy is one of the few areas where Republican lawmakers have pushed back against the Trump administration, but their resolve is being tested with the Pentagon's review of AUKUS. So far, they have joined their Democratic colleagues in voicing support for the partnership. They said the U.S. submarine industry is rebounding with congressional appropriations totaling $10 billion since 2018 to ensure the U.S. will have enough ships to allow for sales to Australia. Sen. Tim Kaine, D-Va., told the AP that support for AUKUS is strong and bipartisan, 'certainly on the Armed Services Committee.' "There is a little bit of mystification about the analysis done at the Pentagon,' Kaine said, adding that 'maybe (what) the analysis will say is: We believe this is a good thing.'
Business Upturn
an hour ago
- Business Upturn
Optimove Reports Reveal 80%+ of US Consumers Have Anxiety Over Tariffs Across 2025 Shopping Seasons
New York, Aug. 11, 2025 (GLOBE NEWSWIRE) — Optimove Insights, the research and analysis arm of Optimove, today released new findings showing that American consumers are increasingly concerned about the impact of tariffs on their spending power. Data from Optimove Insights' surveys of 1,066 US consumers aged 18–65 with household incomes over $75,000 on summer, back-to-school, and pre-holiday shopping periods revealed a consistent theme: more than 81.4% of shoppers are worried about tariffs, and 80.5% are concerned about inflation. Optimove, the creator of Positionless Marketing, frees marketing teams from the limitations of fixed roles, giving every marketer the power to execute any marketing task instantly and independently. Its platform is used by leading global B2C brands. 'These findings are a wake-up call for marketers,' said Pini Yakuel, CEO of Optimove. 'Now more than ever, consumers feel economic pressures. Marketers need agility and empathy to respond in real time. Brands must acknowledge financial anxiety through supportive, empathetic messaging.' Survey results also revealed that while consumers are anxious, many remain willing to spend if presented with value and trust-driven engagement. Irrelevant messaging leads to fatigue and missed opportunities. Yakuel added, 'Brands that cannot listen to consumers' needs and wants and respond in real time will appear tone-deaf. Positionless Marketing helps eliminate these inefficiencies by enabling smarter, more personalized engagement at scale.' About Optimove Optimove, the creator of Positionless Marketing, frees marketing teams from the limitations of fixed roles, giving every marketer the power to execute any marketing task instantly and independently. Positionless Marketing has been proven to improve campaign efficiency by 88%, allowing marketing teams to create more personalized engagement with existing customers. Optimove is recognized as the Visionary Leader in Gartner's Magic Quadrant for Multichannel Marketing Hubs. Being a visionary leader is a hallmark of Optimove. It was the first CRM Marketing Platform to natively embed AI with the ability to predict customer migrations between lifecycle stages in 2012. Today, its comprehensive AI-powered suite is at the leading edge of empowering marketers to optimize workflows from Insight to Creation and through Orchestration. Optimove provides industry-specific and use-case solutions for leading consumer brands globally. For more information, go to About Optimove Insights
